{"gene":"SNCA","run_date":"2026-06-10T07:46:37","timeline":{"discoveries":[{"year":1996,"finding":"NACP (alpha-synuclein) is a natively unfolded protein: it has a larger Stokes radius and slower sedimentation than globular proteins of similar molecular weight, lacks significant secondary structure (by CD and FTIR), lacks a hydrophobic core, and its conformation is unchanged by boiling, pH, salt, or chemical denaturants, indicating it exists as a mixture of rapidly equilibrating extended conformers.","method":"Analytical ultracentrifugation, gel filtration, circular dichroism (CD), Fourier-transform infrared spectroscopy (FTIR), UV spectroscopy","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal biophysical methods (AUC, CD, FTIR, UV) in a single rigorous study with consistent conclusions; foundational result widely replicated","pmids":["8901511"],"is_preprint":false},{"year":1995,"finding":"NACP (alpha-synuclein) binds to amyloid beta (Aβ) peptides through its NAC domain (specifically requiring the hydrophobic region of Aβ, residues 25–35), and at a 1:125 molar ratio promotes Aβ aggregation in aqueous solution; a deletion mutant lacking the NAC domain does not bind Aβ.","method":"Nitrocellulose filter-binding assay with recombinant NACP produced in E. coli, deletion mutagenesis (NACP-delta lacking NAC domain), peptide competition assay, aggregation assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with deletion mutagenesis and competition assays; single lab but multiple orthogonal methods","pmids":["7568089"],"is_preprint":false},{"year":1997,"finding":"NACP (alpha-synuclein) exhibits an extended, largely random-coil structure in solution: it migrates anomalously on gel-filtration with an apparent molecular mass of ~70 kDa (true MW ~14 kDa), is extremely sensitive to limited proteolysis, and CD spectra confirm predominantly unfolded conformation.","method":"FPLC gel-filtration chromatography, chemical cross-linking, limited proteolysis, circular dichroism","journal":"Molecules and cells","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — multiple biophysical methods in a single study; replicates conclusions of PMID 8901511 using independent approaches but single lab","pmids":["9085269"],"is_preprint":false},{"year":2001,"finding":"NACP-Rep1, a polymorphic microsatellite ~10 kb upstream of SNCA, acts as a negative modulator of SNCA transcription, with different alleles producing up to 3-fold variation in luciferase reporter expression in SH-SY5Y neuroblastoma cells; an 880 bp fragment containing NACP-Rep1 is necessary for normal expression and two flanking domains interact to enhance expression.","method":"Luciferase reporter assay with deletion constructs spanning 10.7 kb upstream of SNCA in 293T and SH-SY5Y cells, allele-specific reporter constructs","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean reporter assay with multiple deletion constructs and allele variants; single lab, cell-culture model","pmids":["11751692"],"is_preprint":false},{"year":2005,"finding":"PARP-1 (poly-ADP-ribose polymerase-1) binds specifically to the NACP-Rep1 microsatellite upstream of SNCA and down-regulates SNCA transcription in a Rep1-dependent manner; inhibition of PARP-1 catalytic activity increases endogenous SNCA mRNA levels in SH-SY5Y cells.","method":"Pulldown of Rep1-binding proteins followed by mass spectrometry identification; EMSA (electrophoresis mobility shift assay); chromatin immunoprecipitation (ChIP); luciferase reporter assay; pharmacological inhibition of PARP-1 with 3-aminobenzamide; qRT-PCR of endogenous SNCA mRNA","journal":"American journal of human genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal identification (MS + EMSA + ChIP) plus functional validation with inhibitor and reporter assay; multiple orthogonal methods in one study","pmids":["15672325"],"is_preprint":false},{"year":2014,"finding":"DNA methylation at SNCA intron 1 regulates SNCA transcription; targeted methylation editing using dCas9-DNMT3A at intron 1 in iPSC-derived dopaminergic neurons from a patient with SNCA triplication reduced SNCA mRNA and protein levels and rescued disease-related phenotypes (mitochondrial ROS production and reduced cellular viability).","method":"CRISPR-dCas9 fused to DNMT3A catalytic domain (lentiviral delivery); hiPSC-derived dopaminergic neurons; qRT-PCR; Western blot; mitochondrial ROS assay; cell viability assay","journal":"Molecular therapy","confidence":"High","confidence_rationale":"Tier 2 / Moderate — locus-specific epigenetic editing with functional phenotypic rescue; multiple outcome measures in patient-derived neurons; single lab","pmids":["30266652"],"is_preprint":false},{"year":2021,"finding":"H3K4me3 is significantly elevated at the SNCA promoter in substantia nigra neurons of PD patients; CRISPR/dCas9-SunTag-JARID1A-mediated locus-specific demethylation of H3K4me3 at the SNCA promoter reduced alpha-synuclein mRNA and protein in SH-SY5Y cells and iPSC-derived dopaminergic neurons from idiopathic PD patients.","method":"ChIP-seq/ChIP analysis of post-mortem brain; CRISPR/dCas9-SunTag-JARID1A system; qRT-PCR; Western blot; iPSC-derived dopaminergic neurons; NeuN-sorted neuronal nuclei","journal":"EMBO molecular medicine","confidence":"High","confidence_rationale":"Tier 2 / Moderate — locus-specific histone modification editing with functional validation; patient post-mortem tissue plus iPSC model; multiple orthogonal methods; single lab","pmids":["33428332"],"is_preprint":false},{"year":2014,"finding":"The H50Q SNCA mutation increases the rate of alpha-synuclein aggregation into amyloid fibrils in vitro, whereas the G51D mutation has the opposite effect (decreased aggregation rate), yet both mutant proteins can be seeded to form intracellular aggregates by exogenous amyloidogenic seeds and promote cellular toxicity under stress conditions.","method":"Recombinant protein aggregation assay (bis-styrylbenzene fluorometry), sedimentation analysis, electron microscopy, atomic force microscopy, cell-based aggregation seeding assay, cell viability assay","journal":"Journal of neurochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with multiple biophysical methods plus cell-based validation; single lab","pmids":["24984882"],"is_preprint":false},{"year":2023,"finding":"Cryo-EM structures of alpha-synuclein filaments extracted from a case of juvenile-onset synucleinopathy (caused by a 21-nucleotide SNCA duplication) reveal a novel fold (residues 36–100 forming a compact core) that differs from Lewy body disease and MSA folds; the fold shares partial structural similarity with MSA protofilament substructures and contains a non-proteinaceous cofactor binding site; in vitro assembly of recombinant wild-type and insertion-mutant alpha-synuclein did not reproduce the JOS fold.","method":"Electron cryo-microscopy (cryo-EM) structure determination of patient-derived sarkosyl-insoluble filaments; in vitro assembly of recombinant proteins; mass spectrometry","journal":"Acta neuropathologica","confidence":"High","confidence_rationale":"Tier 1 / Moderate — atomic-resolution cryo-EM structure of patient-derived filaments with in vitro validation; single study but rigorous structural method","pmids":["36847833"],"is_preprint":false},{"year":2014,"finding":"Autophagy-lysosomal pathway (ALP) inhibition by bafilomycin A1 reduces intracellular SNCA aggregation but increases secretion of smaller oligomeric SNCA species predominantly via exosomes and RAB11A-associated pathways, whereas high-aggregated SNCA is secreted by membrane shedding; the secreted oligomers exacerbate microenvironmental toxicity.","method":"Cell culture model of SNCA aggregation; SNCA transgenic mice; pharmacological ALP inhibition (bafilomycin A1); immunoprecipitation; ELISA; live-cell imaging; exosome isolation; inflammation and cell-damage assays","journal":"Autophagy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal approaches (cell model + mouse model + exosome fractionation + pathway inhibition); single lab","pmids":["25484190"],"is_preprint":false},{"year":2015,"finding":"Loss of GBA (glucocerebrosidase) function increases SNCA levels by inhibiting autophagy via PPP2A (protein phosphatase 2A) inactivation through Tyr307 phosphorylation; activation of PPP2A with C2-ceramide or rapamycin reverses GBA knockdown-induced SNCA accumulation.","method":"siRNA knockdown of GBA in SK-N-SH cells and primary rat cortical neurons; pharmacological inhibition; Western blot; immunohistochemistry; flow cytometry; rat striatum in vivo model","journal":"Autophagy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockdown with pharmacological rescue in multiple cell types and in vivo; single lab, mechanistic pathway placement","pmids":["26378614"],"is_preprint":false},{"year":2017,"finding":"BAG3 interacts with HSP70 and sequestosome 1 (SQSTM1/p62) and co-localizes with these proteins and LC3 puncta in TH-positive neurons; BAG3 overexpression enhances autophagic degradation of SNCA, and this effect is prevented by ATG5 knockdown, placing BAG3 upstream of macroautophagy in SNCA clearance.","method":"Immunoprecipitation; immunostaining; Western blot; BAG3 overexpression and knockdown in PC12 cells; SNCAA53T transgenic mice; ATG5 siRNA knockdown","journal":"Neurobiology of aging","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP plus epistasis (ATG5 KD rescue) in cell lines and transgenic mice; single lab","pmids":["28941726"],"is_preprint":false},{"year":2013,"finding":"ABL1 tyrosine kinase is activated by SNCA expression (via phosphorylation) and in turn increases SNCA levels; inhibition of ABL1 with Nilotinib facilitates autophagic clearance of SNCA, shifting SNCA from autophagic vacuoles to lysosomes in transgenic and lentiviral mouse models.","method":"Lentiviral SNCA expression in mouse substantia nigra; lentiviral Abl overexpression; Nilotinib pharmacological treatment; subcellular fractionation; Western blot; transgenic mouse model","journal":"Autophagy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic and pharmacological manipulation with subcellular fractionation; multiple model systems; single lab","pmids":["23787811"],"is_preprint":false},{"year":2022,"finding":"CTSD (cathepsin D) is a lysosomal protease critical for SNCA degradation; recombinant human pro-CTSD (rHsCTSD) is endocytosed by neuronal cells, trafficked to lysosomes, and matured into an active enzyme that reduces insoluble SNCA in iPSC-derived dopaminergic neurons from PD patients with A53T SNCA mutation and in ctsd-deficient mouse brain.","method":"Recombinant protein treatment; immunofluorescence; Western blot; iPSC-derived dopaminergic neurons; ctsd-knockout mice; lysosomal activity assays; structured illumination microscopy","journal":"Autophagy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — enzyme replacement approach with functional validation in patient-derived neurons and mouse model; single lab, multiple orthogonal readouts","pmids":["35287553"],"is_preprint":false},{"year":2020,"finding":"In SNCA knock-in mice expressing aSyn-GFP under native regulatory elements, aSyn-GFP disperses from synaptic vesicles upon membrane depolarization, establishing that alpha-synuclein dynamically associates with synaptic vesicles and releases upon neuronal activity.","method":"Snca-GFP knock-in mouse; live imaging of synaptic terminals; membrane depolarization; confocal microscopy; intracerebral injection of preformed fibrils","journal":"eNeuro","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct live-imaging experiment in physiological knock-in model with functional stimulus; single lab","pmids":["32788297"],"is_preprint":false},{"year":2021,"finding":"miR-30b directly binds to the 3'-UTR of SNCA mRNA and suppresses SNCA protein expression in SH-SY5Y cells, as demonstrated by luciferase reporter assay; miR-30b overexpression reduces SNCA protein levels and attenuates MPP+-induced apoptosis.","method":"Luciferase 3'-UTR reporter assay; miR-30b mimics/inhibitors transfection; Western blot; cell viability (CCK assay); apoptosis markers","journal":"Brain and behavior","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — direct 3'-UTR binding validated by luciferase assay with functional phenotypic rescue; single lab, single reporter method for binding","pmids":["32154657"],"is_preprint":false},{"year":2021,"finding":"SNCA mRNA transcript levels are significantly reduced in neurons containing compact alpha-synuclein inclusions (but not in neurons with punctate or no alpha-synuclein staining) in the substantia nigra and amygdala of LBD patients, predominantly in the cytoplasmic compartment, suggesting progressive depletion of SNCA transcription or mRNA as inclusions form.","method":"RNAscope in situ hybridization combined with immunofluorescence for disease-associated alpha-synuclein in post-mortem LBD brain; single-nucleus RNA sequencing of non-diseased frontal cortex","journal":"Acta neuropathologica communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — quantitative in situ hybridization with immunofluorescence co-localization in patient tissue plus single-nucleus RNA-seq; single study","pmids":["37996943"],"is_preprint":false},{"year":2021,"finding":"A novel SNCA A30G mutation causes a local perturbation of the intrinsically disordered structure of alpha-synuclein, slightly perturbs membrane binding, and promotes fibril formation in vitro.","method":"Biophysical characterization of recombinant A30G alpha-synuclein by NMR and other methods; fibril formation assay; whole exome sequencing and haplotype analysis","journal":"Movement disorders","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — biophysical characterization with fibril assay; single lab report of novel mutation","pmids":["33617693"],"is_preprint":false},{"year":1997,"finding":"NACP (alpha-synuclein) is loosely associated with the plasma membrane, endomembrane system, and occasionally the membrane of secretory alpha-granules in platelets, as determined by immunogold electron microscopy.","method":"Immunogold electron microscopy of human platelets; immunoblotting; phorbol ester-induced megakaryocytic differentiation of K562 cells","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — direct subcellular localization by immunogold EM; single lab, single localization method","pmids":["9299413"],"is_preprint":false}],"current_model":"SNCA encodes alpha-synuclein, a natively unfolded presynaptic protein that dynamically associates with synaptic vesicles and disperses upon membrane depolarization; its expression is regulated at multiple levels including transcriptional modulation by the NACP-Rep1 microsatellite (via PARP-1 binding) and epigenetic control through DNA methylation at intron 1 and H3K4me3 at the promoter; alpha-synuclein binds amyloid-beta peptides via its NAC domain and promotes Aβ aggregation; pathogenic missense mutations (e.g., H50Q, G51D, A30G) divergently alter fibril formation kinetics; the protein is cleared primarily through the autophagy-lysosomal pathway involving CTSD, BAG3-HSP70-p62 complexes, and CMA (LAMP2A-dependent), with GBA deficiency impairing this clearance via PPP2A inactivation and ABL1 activation also impeding autophagic flux; excess or aggregated alpha-synuclein is secreted extracellularly via exosomes (RAB11A-associated) or membrane shedding, and cryo-EM has revealed that distinct disease-specific protein folds (differing between Lewy body disease, MSA, and juvenile-onset synucleinopathy) underlie the spectrum of synucleinopathies."},"narrative":{"mechanistic_narrative":"SNCA encodes alpha-synuclein, a natively unfolded, intrinsically disordered presynaptic protein that exists in solution as a mixture of rapidly equilibrating extended conformers lacking stable secondary structure or a hydrophobic core [PMID:8901511, PMID:9085269]. In neurons it dynamically associates with synaptic vesicles and disperses upon membrane depolarization, linking its membrane interactions to neuronal activity [PMID:32788297], and it is loosely associated with plasma and endomembranes [PMID:9299413]. Through its central NAC domain alpha-synuclein binds amyloid-beta peptides and promotes their aggregation, and this same aggregation-prone region drives its own conversion into amyloid fibrils [PMID:7568089]; pathogenic missense mutations divergently tune this process, with H50Q accelerating and G51D slowing fibril formation while A30G locally perturbs the disordered structure to promote fibrillization [PMID:24984882, PMID:33617693]. Cryo-EM of patient-derived filaments establishes that distinct disease-specific folds underlie the synucleinopathy spectrum, including a novel compact fold (residues 36–100) in juvenile-onset disease that cannot be reproduced by in vitro assembly of recombinant protein, implicating a non-proteinaceous cofactor [PMID:36847833]. SNCA dosage is controlled at multiple regulatory layers: transcriptionally by the upstream NACP-Rep1 microsatellite, which recruits PARP-1 to repress transcription [PMID:15672325]; epigenetically by DNA methylation at intron 1 and H3K4me3 at the promoter, both of which directly tune mRNA and protein levels [PMID:30266652, PMID:33428332]; and post-transcriptionally by miR-30b binding the 3'-UTR [PMID:32154657]. Alpha-synuclein is cleared chiefly through the autophagy-lysosomal pathway, requiring lysosomal cathepsin D for degradation [PMID:35287553] and a BAG3–HSP70–p62 complex that routes it into macroautophagy [PMID:28941726]; this clearance is impaired by GBA loss acting through PPP2A inactivation [PMID:26378614] and by ABL1 kinase activation [PMID:23787811], while autophagy blockade redirects oligomeric species to exosomal secretion [PMID:25484190].","teleology":[{"year":1995,"claim":"Established that alpha-synuclein physically engages amyloid-beta through its NAC domain and promotes Aβ aggregation, defining the aggregation-prone module central to its later disease biology.","evidence":"Filter-binding, deletion mutagenesis (NAC-deleted mutant), and aggregation assays with recombinant protein","pmids":["7568089"],"confidence":"High","gaps":["Did not establish whether NAC-mediated self-assembly occurs under physiological conditions","No structural model of the bound complex"]},{"year":1996,"claim":"Resolved the basic biophysical nature of the protein, showing it is natively unfolded rather than globular, which reframed how its function and aggregation must be understood.","evidence":"Analytical ultracentrifugation, CD, FTIR, UV on purified protein, confirmed by independent gel-filtration/proteolysis study (1997)","pmids":["8901511","9085269"],"confidence":"High","gaps":["Did not address conformations adopted upon membrane or partner binding","No in-cell conformational data"]},{"year":1997,"claim":"Provided the first subcellular localization, placing the protein at plasma and endomembranes and secretory granule membranes.","evidence":"Immunogold electron microscopy of human platelets","pmids":["9299413"],"confidence":"Medium","gaps":["Single localization method without neuronal context","Did not define membrane-binding determinants"]},{"year":2001,"claim":"Identified the upstream NACP-Rep1 microsatellite as a cis-regulatory modulator of SNCA transcription, providing a dosage-control mechanism relevant to expression-driven disease.","evidence":"Luciferase reporter assays with deletion and allele-specific constructs in neuroblastoma cells","pmids":["11751692"],"confidence":"Medium","gaps":["Did not identify the trans-acting factor","Cell-culture reporter context only"]},{"year":2005,"claim":"Named PARP-1 as the trans-acting factor binding NACP-Rep1 to repress SNCA, mechanistically completing the upstream regulatory model.","evidence":"Rep1 pulldown/MS, EMSA, ChIP, PARP-1 inhibition, and endogenous mRNA qRT-PCR in SH-SY5Y cells","pmids":["15672325"],"confidence":"High","gaps":["Did not establish in vivo relevance in brain","Connection between PARP-1 enzymatic activity and repression incompletely defined"]},{"year":2013,"claim":"Defined a feed-forward loop in which ABL1 kinase activation by alpha-synuclein impedes its own autophagic clearance, identifying a druggable node (Nilotinib).","evidence":"Lentiviral SNCA/Abl expression, Nilotinib treatment, subcellular fractionation in transgenic and lentiviral mouse models","pmids":["23787811"],"confidence":"Medium","gaps":["Direct phosphorylation substrate relationships not fully mapped","Single lab"]},{"year":2014,"claim":"Showed that pathogenic missense mutations divergently alter fibril formation kinetics, dissociating aggregation rate from cellular toxicity potential.","evidence":"Recombinant aggregation assays (fluorometry, EM, AFM) plus cell-based seeding and viability for H50Q and G51D","pmids":["24984882"],"confidence":"High","gaps":["Did not resolve mutation-specific fibril architecture","Stress-condition toxicity mechanism not defined"]},{"year":2014,"claim":"Linked autophagy capacity to secretion route, demonstrating that ALP inhibition lowers intracellular aggregation but redirects oligomers to exosomal/RAB11A and shedding-based secretion that worsens microenvironmental toxicity.","evidence":"Cell and transgenic mouse models, bafilomycin A1, exosome fractionation, toxicity assays","pmids":["25484190"],"confidence":"Medium","gaps":["Molecular machinery selecting exosome versus shedding routes not defined","Single lab"]},{"year":2014,"claim":"Established intron 1 DNA methylation as a direct, editable lever on SNCA expression with phenotypic consequences in patient neurons.","evidence":"dCas9-DNMT3A targeted methylation in iPSC-derived dopaminergic neurons from an SNCA-triplication patient, with ROS and viability rescue","pmids":["30266652"],"confidence":"High","gaps":["Endogenous regulators establishing this methylation unknown","Single patient line"]},{"year":2015,"claim":"Placed GBA loss-of-function upstream of SNCA accumulation through a PPP2A-inactivation, autophagy-suppressing mechanism, mechanistically connecting a major genetic risk gene to clearance failure.","evidence":"GBA siRNA knockdown with PPP2A-activating rescue in cells, neurons, and rat striatum","pmids":["26378614"],"confidence":"Medium","gaps":["Precise step of autophagy regulated by PPP2A not pinpointed","Single lab"]},{"year":2017,"claim":"Defined a BAG3–HSP70–p62 chaperone module that channels alpha-synuclein into macroautophagy, identifying the adaptor machinery for its degradation.","evidence":"Co-IP, colocalization, BAG3 gain/loss with ATG5-knockdown epistasis in PC12 cells and A53T transgenic mice","pmids":["28941726"],"confidence":"Medium","gaps":["Reciprocal validation of each interaction limited","Selectivity for alpha-synuclein over other substrates unclear"]},{"year":2020,"claim":"Demonstrated activity-dependent synaptic vesicle association in a physiological knock-in model, grounding the protein's normal presynaptic role.","evidence":"Snca-GFP knock-in mouse with live terminal imaging during depolarization","pmids":["32788297"],"confidence":"Medium","gaps":["Functional consequence of dispersal for vesicle cycling not defined","Did not identify vesicle-binding partners"]},{"year":2021,"claim":"Identified H3K4me3 enrichment at the SNCA promoter in PD substantia nigra and showed locus-specific demethylation lowers expression, adding a histone-mark regulatory layer.","evidence":"ChIP on post-mortem brain plus dCas9-SunTag-JARID1A editing in SH-SY5Y and iPSC-derived neurons","pmids":["33428332"],"confidence":"High","gaps":["Writers/erasers maintaining the mark endogenously not defined","Single lab"]},{"year":2021,"claim":"Established miR-30b as a direct 3'-UTR-binding repressor of SNCA with protective phenotypic effects, adding post-transcriptional control.","evidence":"Luciferase 3'-UTR reporter, miR-30b mimics/inhibitors, viability and apoptosis assays in SH-SY5Y under MPP+","pmids":["32154657"],"confidence":"Medium","gaps":["Single reporter method for binding without endogenous target validation","In vivo relevance untested"]},{"year":2021,"claim":"Showed that SNCA mRNA is depleted specifically in neurons bearing compact inclusions, linking inclusion formation to transcript loss.","evidence":"RNAscope with immunofluorescence in post-mortem LBD brain plus single-nucleus RNA-seq","pmids":["37996943"],"confidence":"Medium","gaps":["Causal direction (depletion driving versus following inclusions) unresolved","Correlative tissue analysis"]},{"year":2021,"claim":"Characterized the A30G mutation as a local disorder perturbation that promotes fibrillization, expanding the genotype–aggregation map.","evidence":"NMR and biophysical characterization with fibril assay, plus exome/haplotype analysis of patient","pmids":["33617693"],"confidence":"Medium","gaps":["Cellular toxicity not directly assessed","Single-family report"]},{"year":2022,"claim":"Identified cathepsin D as the lysosomal protease executing SNCA degradation and showed enzyme delivery reduces insoluble protein, defining a terminal clearance step.","evidence":"Recombinant pro-CTSD uptake/maturation in iPSC-derived A53T neurons and ctsd-knockout mouse brain","pmids":["35287553"],"confidence":"Medium","gaps":["Cleavage sites and fragment fate not mapped","Single lab"]},{"year":2023,"claim":"Resolved disease-specific atomic folds of patient-derived filaments, including a novel juvenile-onset fold not reproducible in vitro, establishing structural strain diversity and a cofactor requirement.","evidence":"Cryo-EM of sarkosyl-insoluble filaments from JOS, with recombinant in vitro assembly and mass spectrometry","pmids":["36847833"],"confidence":"High","gaps":["Identity of the non-proteinaceous cofactor unknown","Mechanism generating strain-specific folds in vivo undefined"]},{"year":null,"claim":"How activity-dependent synaptic function, multilayered dosage control, and clearance failure converge to nucleate the distinct cofactor-dependent fibril strains that define each synucleinopathy remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No mechanism linking native synaptic-vesicle biology to strain-specific aggregation","Identity of cofactors templating disease-specific folds unknown","How clearance impairment selects secretion/spreading routes in vivo undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[14,18]},{"term_id":"GO:0005198","term_label":"structural molecule activity","supporting_discovery_ids":[7,8]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[18]},{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[14,9]}],"pathway":[{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[9,10,11,12,13]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[7,8,17]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[4,5,6]}],"complexes":[],"partners":["PARP1","BAG3","HSPA8","SQSTM1","ABL1","CTSD","APP"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P37840","full_name":"Alpha-synuclein","aliases":["Non-A beta component of AD amyloid","Non-A4 component of amyloid precursor","NACP"],"length_aa":140,"mass_kda":14.5,"function":"Neuronal protein that plays several roles in synaptic activity such as regulation of synaptic vesicle trafficking and subsequent neurotransmitter release (PubMed:20798282, PubMed:26442590, PubMed:28288128, PubMed:30404828). Participates as a monomer in synaptic vesicle exocytosis by enhancing vesicle priming, fusion and dilation of exocytotic fusion pores (PubMed:28288128, PubMed:30404828). Mechanistically, acts by increasing local Ca(2+) release from microdomains which is essential for the enhancement of ATP-induced exocytosis (PubMed:30404828). Also acts as a molecular chaperone in its multimeric membrane-bound state, assisting in the folding of synaptic fusion components called SNAREs (Soluble NSF Attachment Protein REceptors) at presynaptic plasma membrane in conjunction with cysteine string protein-alpha/DNAJC5 (PubMed:20798282). This chaperone activity is important to sustain normal SNARE-complex assembly during aging (PubMed:20798282). Also plays a role in the regulation of the dopamine neurotransmission by associating with the dopamine transporter (DAT1) and thereby modulating its activity (PubMed:26442590)","subcellular_location":"Cytoplasm; Membrane; Nucleus; Synapse; Secreted; Cell projection, axon","url":"https://www.uniprot.org/uniprotkb/P37840/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/SNCA","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/SNCA","total_profiled":1310},"omim":[{"mim_id":"621516","title":"DIFFERENTIALLY EXPRESSED IN FDCP 8, MOUSE, HOMOLOG OF; DEF8","url":"https://www.omim.org/entry/621516"},{"mim_id":"621213","title":"FAMILY WITH SEQUENCE SIMILARITY 171, MEMBER A2; FAM171A2","url":"https://www.omim.org/entry/621213"},{"mim_id":"620636","title":"NEURODEGENERATION, CHILDHOOD-ONSET, WITH CEREBELLAR ATAXIA AND COGNITIVE DECLINE; CONDCAC","url":"https://www.omim.org/entry/620636"},{"mim_id":"620215","title":"MEMBRANE INTEGRAL NOTCH2-ASSOCIATED RECEPTOR 2; MINAR2","url":"https://www.omim.org/entry/620215"},{"mim_id":"620048","title":"RETENTION IN ENDOPLASMIC RETICULUM SORTING RECEPTOR 1; RER1","url":"https://www.omim.org/entry/620048"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Group enriched","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"bone marrow","ntpm":257.8},{"tissue":"brain","ntpm":263.1}],"url":"https://www.proteinatlas.org/search/SNCA"},"hgnc":{"alias_symbol":["NACP","PD1"],"prev_symbol":["PARK1","PARK4"]},"alphafold":{"accession":"P37840","domains":[],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P37840","model_url":"https://alphafold.ebi.ac.uk/files/AF-P37840-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P37840-F1-predicted_aligned_error_v6.png","plddt_mean":75.19},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=SNCA","jax_strain_url":"https://www.jax.org/strain/search?query=SNCA"},"sequence":{"accession":"P37840","fasta_url":"https://rest.uniprot.org/uniprotkb/P37840.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P37840/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P37840"}},"corpus_meta":[{"pmid":"8901511","id":"PMC_8901511","title":"NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded.","date":"1996","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8901511","citation_count":1297,"is_preprint":false},{"pmid":"20506312","id":"PMC_20506312","title":"Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update.","date":"2010","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/20506312","citation_count":402,"is_preprint":false},{"pmid":"9466562","id":"PMC_9466562","title":"Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders.","date":"1998","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/9466562","citation_count":367,"is_preprint":false},{"pmid":"9547168","id":"PMC_9547168","title":"NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease.","date":"1997","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/9547168","citation_count":283,"is_preprint":false},{"pmid":"18162487","id":"PMC_18162487","title":"Genetic variability in the SNCA gene influences alpha-synuclein levels in the blood and brain.","date":"2007","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/18162487","citation_count":208,"is_preprint":false},{"pmid":"11751692","id":"PMC_11751692","title":"Effect of allelic variation at the NACP-Rep1 repeat upstream of the alpha-synuclein gene (SNCA) on transcription in a cell culture luciferase reporter system.","date":"2001","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11751692","citation_count":204,"is_preprint":false},{"pmid":"25484190","id":"PMC_25484190","title":"Autophagy modulates SNCA/α-synuclein release, thereby generating a hostile microenvironment.","date":"2014","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/25484190","citation_count":186,"is_preprint":false},{"pmid":"10528110","id":"PMC_10528110","title":"Cellular co-localization of phosphorylated tau- and NACP/alpha-synuclein-epitopes in lewy bodies in sporadic Parkinson's disease and in dementia with Lewy bodies.","date":"1999","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/10528110","citation_count":179,"is_preprint":false},{"pmid":"30983487","id":"PMC_30983487","title":"Age-dependent accumulation of oligomeric SNCA/α-synuclein from impaired degradation in mutant LRRK2 knockin mouse model of Parkinson disease: role for therapeutic activation of chaperone-mediated autophagy (CMA).","date":"2019","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/30983487","citation_count":177,"is_preprint":false},{"pmid":"7568089","id":"PMC_7568089","title":"NACP, the precursor protein of the non-amyloid beta/A4 protein (A beta) component of Alzheimer disease amyloid, binds A beta and stimulates A beta aggregation.","date":"1995","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/7568089","citation_count":177,"is_preprint":false},{"pmid":"25178429","id":"PMC_25178429","title":"APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease.","date":"2014","source":"JAMA neurology","url":"https://pubmed.ncbi.nlm.nih.gov/25178429","citation_count":171,"is_preprint":false},{"pmid":"26350119","id":"PMC_26350119","title":"Autosomal dominant Parkinson's disease caused by SNCA duplications.","date":"2015","source":"Parkinsonism & related disorders","url":"https://pubmed.ncbi.nlm.nih.gov/26350119","citation_count":167,"is_preprint":false},{"pmid":"30357936","id":"PMC_30357936","title":"Genotype-phenotype relations for the Parkinson's disease genes SNCA, LRRK2, VPS35: MDSGene systematic review.","date":"2018","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/30357936","citation_count":155,"is_preprint":false},{"pmid":"30266652","id":"PMC_30266652","title":"Downregulation of SNCA Expression by Targeted Editing of DNA Methylation: A Potential Strategy for Precision Therapy in PD.","date":"2018","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/30266652","citation_count":150,"is_preprint":false},{"pmid":"21060011","id":"PMC_21060011","title":"SNCA variant associated with Parkinson disease and plasma alpha-synuclein level.","date":"2010","source":"Archives of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/21060011","citation_count":148,"is_preprint":false},{"pmid":"8546207","id":"PMC_8546207","title":"Altered presynaptic protein NACP is associated with plaque formation and neurodegeneration in Alzheimer's disease.","date":"1996","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/8546207","citation_count":147,"is_preprint":false},{"pmid":"27080380","id":"PMC_27080380","title":"The Parkinson Disease gene SNCA: Evolutionary and structural insights with pathological implication.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27080380","citation_count":124,"is_preprint":false},{"pmid":"29989488","id":"PMC_29989488","title":"The lysosomal membrane protein LAMP2A promotes autophagic flux and prevents SNCA-induced Parkinson disease-like symptoms in the Drosophila brain.","date":"2018","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/29989488","citation_count":117,"is_preprint":false},{"pmid":"18413475","id":"PMC_18413475","title":"Patients homozygous and heterozygous for SNCA duplication in a family with parkinsonism and dementia.","date":"2008","source":"Archives of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/18413475","citation_count":109,"is_preprint":false},{"pmid":"24984882","id":"PMC_24984882","title":"Divergent effects of the H50Q and G51D SNCA mutations on the aggregation of α-synuclein.","date":"2014","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24984882","citation_count":108,"is_preprint":false},{"pmid":"26378614","id":"PMC_26378614","title":"GBA deficiency promotes SNCA/α-synuclein accumulation through autophagic inhibition by inactivated PPP2A.","date":"2015","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/26378614","citation_count":107,"is_preprint":false},{"pmid":"9299413","id":"PMC_9299413","title":"NACP, a synaptic protein involved in Alzheimer's disease, is differentially regulated during megakaryocyte differentiation.","date":"1997","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/9299413","citation_count":101,"is_preprint":false},{"pmid":"26306801","id":"PMC_26306801","title":"Distinct clinical and neuropathological features of G51D SNCA mutation cases compared with SNCA duplication and H50Q mutation.","date":"2015","source":"Molecular neurodegeneration","url":"https://pubmed.ncbi.nlm.nih.gov/26306801","citation_count":99,"is_preprint":false},{"pmid":"33617693","id":"PMC_33617693","title":"A Novel SNCA A30G Mutation Causes Familial Parkinson's Disease.","date":"2021","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/33617693","citation_count":87,"is_preprint":false},{"pmid":"7601450","id":"PMC_7601450","title":"The NACP/synuclein gene: chromosomal assignment and screening for alterations in Alzheimer disease.","date":"1995","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/7601450","citation_count":85,"is_preprint":false},{"pmid":"24326201","id":"PMC_24326201","title":"Hypomethylation of SNCA in blood of patients with sporadic Parkinson's disease.","date":"2013","source":"Journal of the neurological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/24326201","citation_count":83,"is_preprint":false},{"pmid":"21391235","id":"PMC_21391235","title":"Independent and joint effects of the MAPT and SNCA genes in Parkinson disease.","date":"2011","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/21391235","citation_count":78,"is_preprint":false},{"pmid":"15672325","id":"PMC_15672325","title":"Regulation of alpha-synuclein expression by poly (ADP ribose) polymerase-1 (PARP-1) binding to the NACP-Rep1 polymorphic site upstream of the SNCA gene.","date":"2005","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15672325","citation_count":78,"is_preprint":false},{"pmid":"33428332","id":"PMC_33428332","title":"Targeted attenuation of elevated histone marks at SNCA alleviates α-synuclein in Parkinson's disease.","date":"2021","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33428332","citation_count":75,"is_preprint":false},{"pmid":"36847833","id":"PMC_36847833","title":"New SNCA mutation and structures of α-synuclein filaments from juvenile-onset synucleinopathy.","date":"2023","source":"Acta neuropathologica","url":"https://pubmed.ncbi.nlm.nih.gov/36847833","citation_count":70,"is_preprint":false},{"pmid":"10899435","id":"PMC_10899435","title":"Properties of NACP/alpha-synuclein and its role in Alzheimer's disease.","date":"2000","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/10899435","citation_count":70,"is_preprint":false},{"pmid":"34092198","id":"PMC_34092198","title":"Piperine promotes autophagy flux by P2RX4 activation in SNCA/α-synuclein-induced Parkinson disease model.","date":"2021","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/34092198","citation_count":68,"is_preprint":false},{"pmid":"35287553","id":"PMC_35287553","title":"Recombinant pro-CTSD (cathepsin D) enhances SNCA/α-Synuclein degradation in α-Synucleinopathy models.","date":"2022","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/35287553","citation_count":67,"is_preprint":false},{"pmid":"30472757","id":"PMC_30472757","title":"Engineering synucleinopathy-resistant human dopaminergic neurons by CRISPR-mediated deletion of the SNCA gene.","date":"2018","source":"The European journal of neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/30472757","citation_count":67,"is_preprint":false},{"pmid":"24768741","id":"PMC_24768741","title":"Genetic variants and animal models in SNCA and Parkinson disease.","date":"2014","source":"Ageing research reviews","url":"https://pubmed.ncbi.nlm.nih.gov/24768741","citation_count":66,"is_preprint":false},{"pmid":"10963357","id":"PMC_10963357","title":"NACP/alpha-synuclein and tau constitute two distinctive subsets of filaments in the same neuronal inclusions in brains from a family of parkinsonism and dementia with Lewy bodies: double-immunolabeling fluorescence and electron microscopic studies.","date":"2000","source":"Acta neuropathologica","url":"https://pubmed.ncbi.nlm.nih.gov/10963357","citation_count":65,"is_preprint":false},{"pmid":"27717584","id":"PMC_27717584","title":"Parkinson's disease: SNCA-, PARK2-, and LRRK2- targeting microRNAs elevated in cingulate gyrus.","date":"2016","source":"Parkinsonism & related disorders","url":"https://pubmed.ncbi.nlm.nih.gov/27717584","citation_count":63,"is_preprint":false},{"pmid":"25554495","id":"PMC_25554495","title":"Link between the SNCA gene and parkinsonism.","date":"2014","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/25554495","citation_count":61,"is_preprint":false},{"pmid":"34632384","id":"PMC_34632384","title":"Midbrain organoids with an SNCA gene triplication model key features of synucleinopathy.","date":"2021","source":"Brain communications","url":"https://pubmed.ncbi.nlm.nih.gov/34632384","citation_count":60,"is_preprint":false},{"pmid":"28445713","id":"PMC_28445713","title":"Deregulation of α-synuclein in Parkinson's disease: Insight from epigenetic structure and transcriptional regulation of SNCA.","date":"2017","source":"Progress in neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/28445713","citation_count":59,"is_preprint":false},{"pmid":"15670652","id":"PMC_15670652","title":"Australian data and meta-analysis lend support for alpha-synuclein (NACP-Rep1) as a risk factor for Parkinson's disease.","date":"2004","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/15670652","citation_count":53,"is_preprint":false},{"pmid":"30146727","id":"PMC_30146727","title":"A comprehensive analysis of SNCA-related genetic risk in sporadic parkinson disease.","date":"2018","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/30146727","citation_count":53,"is_preprint":false},{"pmid":"28941726","id":"PMC_28941726","title":"A role of BAG3 in regulating SNCA/α-synuclein clearance via selective macroautophagy.","date":"2017","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/28941726","citation_count":52,"is_preprint":false},{"pmid":"9085269","id":"PMC_9085269","title":"Evidence that the precursor protein of non-A beta component of Alzheimer's disease amyloid (NACP) has an extended structure primarily composed of random-coil.","date":"1997","source":"Molecules and cells","url":"https://pubmed.ncbi.nlm.nih.gov/9085269","citation_count":52,"is_preprint":false},{"pmid":"28781905","id":"PMC_28781905","title":"Genetic Variants in SNCA and the Risk of Sporadic Parkinson's Disease and Clinical Outcomes: A Review.","date":"2017","source":"Parkinson's disease","url":"https://pubmed.ncbi.nlm.nih.gov/28781905","citation_count":49,"is_preprint":false},{"pmid":"23787811","id":"PMC_23787811","title":"Tyrosine kinase inhibition facilitates autophagic SNCA/α-synuclein clearance.","date":"2013","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/23787811","citation_count":49,"is_preprint":false},{"pmid":"27685250","id":"PMC_27685250","title":"DNA methylation changes at SNCA intron 1 in patients with dementia with Lewy bodies.","date":"2016","source":"Psychiatry and clinical neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/27685250","citation_count":48,"is_preprint":false},{"pmid":"25802477","id":"PMC_25802477","title":"Detection of SNCA and FBN1 methylation in the stool as a biomarker for colorectal cancer.","date":"2015","source":"Disease markers","url":"https://pubmed.ncbi.nlm.nih.gov/25802477","citation_count":48,"is_preprint":false},{"pmid":"29300342","id":"PMC_29300342","title":"SNCA Is a Functionally Low-Expressed Gene in Lung Adenocarcinoma.","date":"2018","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/29300342","citation_count":48,"is_preprint":false},{"pmid":"22445250","id":"PMC_22445250","title":"Analysis of LRRK2, SNCA, Parkin, PINK1, and DJ-1 in Zambian patients with Parkinson's disease.","date":"2012","source":"Parkinsonism & related disorders","url":"https://pubmed.ncbi.nlm.nih.gov/22445250","citation_count":48,"is_preprint":false},{"pmid":"30536337","id":"PMC_30536337","title":"LncRNA-UCA1 promotes PD development by upregulating SNCA.","date":"2018","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30536337","citation_count":47,"is_preprint":false},{"pmid":"35596947","id":"PMC_35596947","title":"Parkinson's Disease Derived Exosomes Aggravate Neuropathology in SNCA*A53T Mice.","date":"2022","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/35596947","citation_count":46,"is_preprint":false},{"pmid":"27066564","id":"PMC_27066564","title":"Clinical and imaging findings in Parkinson disease associated with the A53E SNCA mutation.","date":"2015","source":"Neurology. Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27066564","citation_count":45,"is_preprint":false},{"pmid":"35191750","id":"PMC_35191750","title":"CRISPR-Cas9 Gene Editing Protects from the A53T-SNCA Overexpression-Induced Pathology of Parkinson's Disease In Vivo.","date":"2022","source":"The CRISPR journal","url":"https://pubmed.ncbi.nlm.nih.gov/35191750","citation_count":42,"is_preprint":false},{"pmid":"17222106","id":"PMC_17222106","title":"Screening for SNCA and LRRK2 mutations in Greek sporadic and autosomal dominant Parkinson's disease: identification of two novel LRRK2 variants.","date":"2007","source":"European journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/17222106","citation_count":41,"is_preprint":false},{"pmid":"22104010","id":"PMC_22104010","title":"SNCA and MAPT genes: Independent and joint effects in Parkinson disease in the Italian population.","date":"2011","source":"Parkinsonism & related disorders","url":"https://pubmed.ncbi.nlm.nih.gov/22104010","citation_count":39,"is_preprint":false},{"pmid":"32677286","id":"PMC_32677286","title":"Evaluating the Role of SNCA, LRRK2, and GBA in Chinese Patients With Early-Onset Parkinson's Disease.","date":"2020","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/32677286","citation_count":39,"is_preprint":false},{"pmid":"34440548","id":"PMC_34440548","title":"The Impact of SNCA Variations and Its Product Alpha-Synuclein on Non-Motor Features of Parkinson's Disease.","date":"2021","source":"Life (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/34440548","citation_count":37,"is_preprint":false},{"pmid":"24721670","id":"PMC_24721670","title":"Pyrosequencing analysis of SNCA methylation levels in leukocytes from Parkinson's disease patients.","date":"2014","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/24721670","citation_count":37,"is_preprint":false},{"pmid":"21159074","id":"PMC_21159074","title":"SNCA, MAPT, and GSK3B in Parkinson disease: a gene-gene interaction study.","date":"2010","source":"European journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/21159074","citation_count":35,"is_preprint":false},{"pmid":"27567856","id":"PMC_27567856","title":"Elevated mRNA Expression and Low Methylation of SNCA in Japanese Alzheimer's Disease Subjects.","date":"2016","source":"Journal of Alzheimer's disease : JAD","url":"https://pubmed.ncbi.nlm.nih.gov/27567856","citation_count":35,"is_preprint":false},{"pmid":"33890542","id":"PMC_33890542","title":"HIV-1 Vpr protein impairs lysosome clearance causing SNCA/alpha-synuclein accumulation in neurons.","date":"2021","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/33890542","citation_count":35,"is_preprint":false},{"pmid":"31870437","id":"PMC_31870437","title":"Investigation of somatic CNVs in brains of synucleinopathy cases using targeted SNCA analysis and single cell sequencing.","date":"2019","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/31870437","citation_count":35,"is_preprint":false},{"pmid":"10766891","id":"PMC_10766891","title":"Accumulation of NACP/alpha-synuclein in lewy body disease and multiple system atrophy.","date":"2000","source":"Journal of neurology, neurosurgery, and psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/10766891","citation_count":33,"is_preprint":false},{"pmid":"21412942","id":"PMC_21412942","title":"SNCA locus duplication carriers: from genetics to Parkinson disease phenotypes.","date":"2011","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/21412942","citation_count":32,"is_preprint":false},{"pmid":"25656566","id":"PMC_25656566","title":"Alpha-synuclein (SNCA) polymorphisms and susceptibility to Parkinson's disease: a meta-analysis.","date":"2015","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25656566","citation_count":31,"is_preprint":false},{"pmid":"32154657","id":"PMC_32154657","title":"miR-30b protects nigrostriatal dopaminergic neurons from MPP(+)-induced neurotoxicity via SNCA.","date":"2020","source":"Brain and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/32154657","citation_count":30,"is_preprint":false},{"pmid":"28676755","id":"PMC_28676755","title":"Variants in SNCA Gene Are Associated with Parkinson's Disease Risk and Cognitive Symptoms in a Brazilian Sample.","date":"2017","source":"Frontiers in aging neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/28676755","citation_count":30,"is_preprint":false},{"pmid":"28078311","id":"PMC_28078311","title":"Common variant rs356182 near SNCA defines a Parkinson's disease endophenotype.","date":"2016","source":"Annals of clinical and translational neurology","url":"https://pubmed.ncbi.nlm.nih.gov/28078311","citation_count":30,"is_preprint":false},{"pmid":"21800132","id":"PMC_21800132","title":"Genetic variability in SNCA and Parkinson's disease.","date":"2011","source":"Neurogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/21800132","citation_count":28,"is_preprint":false},{"pmid":"9555070","id":"PMC_9555070","title":"Changes in presynaptic protein NACP/alpha-synuclein in an ischemic gerbil hippocampus.","date":"1998","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/9555070","citation_count":27,"is_preprint":false},{"pmid":"22425546","id":"PMC_22425546","title":"SNCA polymorphisms, smoking, and sporadic Parkinson's disease in Japanese.","date":"2012","source":"Parkinsonism & related disorders","url":"https://pubmed.ncbi.nlm.nih.gov/22425546","citation_count":27,"is_preprint":false},{"pmid":"26776090","id":"PMC_26776090","title":"Variants in the SNCA gene associate with motor progression while variants in the MAPT gene associate with the severity of Parkinson's disease.","date":"2015","source":"Parkinsonism & related disorders","url":"https://pubmed.ncbi.nlm.nih.gov/26776090","citation_count":27,"is_preprint":false},{"pmid":"34799977","id":"PMC_34799977","title":"α-Synuclein antisense transcript SNCA-AS1 regulates synapses- and aging-related genes suggesting its implication in Parkinson's disease.","date":"2021","source":"Aging cell","url":"https://pubmed.ncbi.nlm.nih.gov/34799977","citation_count":26,"is_preprint":false},{"pmid":"35000546","id":"PMC_35000546","title":"Autophagy mediates the clearance of oligodendroglial SNCA/alpha-synuclein and TPPP/p25A in multiple system atrophy models.","date":"2022","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/35000546","citation_count":25,"is_preprint":false},{"pmid":"30304516","id":"PMC_30304516","title":"Multiplication of the SNCA locus exacerbates neuronal nuclear aging.","date":"2019","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30304516","citation_count":25,"is_preprint":false},{"pmid":"29369502","id":"PMC_29369502","title":"SNCA, a novel biomarker for Group 4 medulloblastomas, can inhibit tumor invasion and induce apoptosis.","date":"2018","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/29369502","citation_count":25,"is_preprint":false},{"pmid":"32788297","id":"PMC_32788297","title":"Snca-GFP Knock-In Mice Reflect Patterns of Endogenous Expression and Pathological Seeding.","date":"2020","source":"eNeuro","url":"https://pubmed.ncbi.nlm.nih.gov/32788297","citation_count":21,"is_preprint":false},{"pmid":"31178336","id":"PMC_31178336","title":"Small fiber neuropathy and phosphorylated alpha-synuclein in the skin of E46K-SNCA mutation carriers.","date":"2019","source":"Parkinsonism & related disorders","url":"https://pubmed.ncbi.nlm.nih.gov/31178336","citation_count":21,"is_preprint":false},{"pmid":"21816655","id":"PMC_21816655","title":"Do interactions between SNCA, MAPT, and LRRK2 genes contribute to Parkinson's disease susceptibility?","date":"2011","source":"Parkinsonism & related disorders","url":"https://pubmed.ncbi.nlm.nih.gov/21816655","citation_count":21,"is_preprint":false},{"pmid":"28108469","id":"PMC_28108469","title":"Blood RNA biomarkers in prodromal PARK4 and rapid eye movement sleep behavior disorder show role of complexin 1 loss for risk of Parkinson's disease.","date":"2017","source":"Disease models & mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/28108469","citation_count":20,"is_preprint":false},{"pmid":"33994928","id":"PMC_33994928","title":"Cell-Type Specific Changes in DNA Methylation of SNCA Intron 1 in Synucleinopathy Brains.","date":"2021","source":"Frontiers in neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/33994928","citation_count":20,"is_preprint":false},{"pmid":"37138318","id":"PMC_37138318","title":"The G51D SNCA mutation generates a slowly progressive α-synuclein strain in early-onset Parkinson's disease.","date":"2023","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/37138318","citation_count":20,"is_preprint":false},{"pmid":"31234232","id":"PMC_31234232","title":"SNCA and mTOR Pathway Single Nucleotide Polymorphisms Interact to Modulate the Age at Onset of Parkinson's Disease.","date":"2019","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/31234232","citation_count":20,"is_preprint":false},{"pmid":"25960998","id":"PMC_25960998","title":"SNCA Gene, but Not MAPT, Influences Onset Age of Parkinson's Disease in Chinese and Australians.","date":"2015","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/25960998","citation_count":19,"is_preprint":false},{"pmid":"33649398","id":"PMC_33649398","title":"Investigating the relationship between the SNCA gene and cognitive abilities in idiopathic Parkinson's disease using machine learning.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/33649398","citation_count":19,"is_preprint":false},{"pmid":"37996943","id":"PMC_37996943","title":"Neuronal SNCA transcription during Lewy body formation.","date":"2023","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/37996943","citation_count":18,"is_preprint":false},{"pmid":"34456707","id":"PMC_34456707","title":"Genetic Analysis and Literature Review of SNCA Variants in Parkinson's Disease.","date":"2021","source":"Frontiers in aging neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/34456707","citation_count":18,"is_preprint":false},{"pmid":"36261424","id":"PMC_36261424","title":"Modeling native and seeded Synuclein aggregation and related cellular dysfunctions in dopaminergic neurons derived by a new set of isogenic iPSC lines with SNCA multiplications.","date":"2022","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/36261424","citation_count":18,"is_preprint":false},{"pmid":"32444558","id":"PMC_32444558","title":"SNCA Hypomethylation in Rapid Eye Movement Sleep Behavior Disorder Is a Potential Biomarker for Parkinson's Disease.","date":"2020","source":"Journal of Parkinson's disease","url":"https://pubmed.ncbi.nlm.nih.gov/32444558","citation_count":18,"is_preprint":false},{"pmid":"28319736","id":"PMC_28319736","title":"Structural variants in SNCA gene and the implication to synucleinopathies.","date":"2017","source":"Current opinion in genetics & development","url":"https://pubmed.ncbi.nlm.nih.gov/28319736","citation_count":17,"is_preprint":false},{"pmid":"36109514","id":"PMC_36109514","title":"Linking the phenotype of SNCA Triplication with PET-MRI imaging pattern and alpha-synuclein CSF seeding.","date":"2022","source":"NPJ Parkinson's disease","url":"https://pubmed.ncbi.nlm.nih.gov/36109514","citation_count":17,"is_preprint":false},{"pmid":"31234238","id":"PMC_31234238","title":"SNCA Rep1 promoter variability influences cognition in Parkinson's disease.","date":"2019","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/31234238","citation_count":17,"is_preprint":false},{"pmid":"30424941","id":"PMC_30424941","title":"Association of SNCA variants with α-synuclein of gastric and colonic mucosa in Parkinson's disease.","date":"2018","source":"Parkinsonism & related disorders","url":"https://pubmed.ncbi.nlm.nih.gov/30424941","citation_count":17,"is_preprint":false},{"pmid":"39199337","id":"PMC_39199337","title":"Novel Therapeutic Horizons: SNCA Targeting in Parkinson's Disease.","date":"2024","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/39199337","citation_count":16,"is_preprint":false},{"pmid":"33362685","id":"PMC_33362685","title":"Metal Exposure and SNCA rs356219 Polymorphism Associated With Parkinson Disease and Parkinsonism.","date":"2020","source":"Frontiers in neurology","url":"https://pubmed.ncbi.nlm.nih.gov/33362685","citation_count":16,"is_preprint":false},{"pmid":"33974284","id":"PMC_33974284","title":"Prodromal sensory neuropathy in Pink1-/- SNCAA53T double mutant Parkinson mice.","date":"2021","source":"Neuropathology and applied neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/33974284","citation_count":16,"is_preprint":false},{"pmid":"33307186","id":"PMC_33307186","title":"A population scale analysis of rare SNCA variation in the UK Biobank.","date":"2020","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/33307186","citation_count":16,"is_preprint":false},{"pmid":"31277379","id":"PMC_31277379","title":"SerThr-PhosphoProteome of Brain from Aged PINK1-KO+A53T-SNCA Mice Reveals pT1928-MAP1B and pS3781-ANK2 Deficits, as Hub between Autophagy and Synapse Changes.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31277379","citation_count":16,"is_preprint":false},{"pmid":"27455133","id":"PMC_27455133","title":"Mutation analysis of the PARKIN, PINK1, DJ1, and SNCA genes in Turkish early-onset Parkinson's patients and genotype-phenotype correlations.","date":"2016","source":"Clinical neurology and neurosurgery","url":"https://pubmed.ncbi.nlm.nih.gov/27455133","citation_count":16,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":54998,"output_tokens":5130,"usd":0.120972,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":13446,"output_tokens":4982,"usd":0.09589,"stage2_stop_reason":"end_turn"},"total_usd":0.216862,"stage1_batch_id":"msgbatch_013LWZZT6MWaqB9qyTSeQBmU","stage2_batch_id":"msgbatch_0194ZzQaTGNpruoNJBbEMbt3","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1996,\n      \"finding\": \"NACP (alpha-synuclein) is a natively unfolded protein: it has a larger Stokes radius and slower sedimentation than globular proteins of similar molecular weight, lacks significant secondary structure (by CD and FTIR), lacks a hydrophobic core, and its conformation is unchanged by boiling, pH, salt, or chemical denaturants, indicating it exists as a mixture of rapidly equilibrating extended conformers.\",\n      \"method\": \"Analytical ultracentrifugation, gel filtration, circular dichroism (CD), Fourier-transform infrared spectroscopy (FTIR), UV spectroscopy\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal biophysical methods (AUC, CD, FTIR, UV) in a single rigorous study with consistent conclusions; foundational result widely replicated\",\n      \"pmids\": [\"8901511\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"NACP (alpha-synuclein) binds to amyloid beta (Aβ) peptides through its NAC domain (specifically requiring the hydrophobic region of Aβ, residues 25–35), and at a 1:125 molar ratio promotes Aβ aggregation in aqueous solution; a deletion mutant lacking the NAC domain does not bind Aβ.\",\n      \"method\": \"Nitrocellulose filter-binding assay with recombinant NACP produced in E. coli, deletion mutagenesis (NACP-delta lacking NAC domain), peptide competition assay, aggregation assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with deletion mutagenesis and competition assays; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"7568089\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"NACP (alpha-synuclein) exhibits an extended, largely random-coil structure in solution: it migrates anomalously on gel-filtration with an apparent molecular mass of ~70 kDa (true MW ~14 kDa), is extremely sensitive to limited proteolysis, and CD spectra confirm predominantly unfolded conformation.\",\n      \"method\": \"FPLC gel-filtration chromatography, chemical cross-linking, limited proteolysis, circular dichroism\",\n      \"journal\": \"Molecules and cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — multiple biophysical methods in a single study; replicates conclusions of PMID 8901511 using independent approaches but single lab\",\n      \"pmids\": [\"9085269\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"NACP-Rep1, a polymorphic microsatellite ~10 kb upstream of SNCA, acts as a negative modulator of SNCA transcription, with different alleles producing up to 3-fold variation in luciferase reporter expression in SH-SY5Y neuroblastoma cells; an 880 bp fragment containing NACP-Rep1 is necessary for normal expression and two flanking domains interact to enhance expression.\",\n      \"method\": \"Luciferase reporter assay with deletion constructs spanning 10.7 kb upstream of SNCA in 293T and SH-SY5Y cells, allele-specific reporter constructs\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean reporter assay with multiple deletion constructs and allele variants; single lab, cell-culture model\",\n      \"pmids\": [\"11751692\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"PARP-1 (poly-ADP-ribose polymerase-1) binds specifically to the NACP-Rep1 microsatellite upstream of SNCA and down-regulates SNCA transcription in a Rep1-dependent manner; inhibition of PARP-1 catalytic activity increases endogenous SNCA mRNA levels in SH-SY5Y cells.\",\n      \"method\": \"Pulldown of Rep1-binding proteins followed by mass spectrometry identification; EMSA (electrophoresis mobility shift assay); chromatin immunoprecipitation (ChIP); luciferase reporter assay; pharmacological inhibition of PARP-1 with 3-aminobenzamide; qRT-PCR of endogenous SNCA mRNA\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal identification (MS + EMSA + ChIP) plus functional validation with inhibitor and reporter assay; multiple orthogonal methods in one study\",\n      \"pmids\": [\"15672325\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"DNA methylation at SNCA intron 1 regulates SNCA transcription; targeted methylation editing using dCas9-DNMT3A at intron 1 in iPSC-derived dopaminergic neurons from a patient with SNCA triplication reduced SNCA mRNA and protein levels and rescued disease-related phenotypes (mitochondrial ROS production and reduced cellular viability).\",\n      \"method\": \"CRISPR-dCas9 fused to DNMT3A catalytic domain (lentiviral delivery); hiPSC-derived dopaminergic neurons; qRT-PCR; Western blot; mitochondrial ROS assay; cell viability assay\",\n      \"journal\": \"Molecular therapy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — locus-specific epigenetic editing with functional phenotypic rescue; multiple outcome measures in patient-derived neurons; single lab\",\n      \"pmids\": [\"30266652\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"H3K4me3 is significantly elevated at the SNCA promoter in substantia nigra neurons of PD patients; CRISPR/dCas9-SunTag-JARID1A-mediated locus-specific demethylation of H3K4me3 at the SNCA promoter reduced alpha-synuclein mRNA and protein in SH-SY5Y cells and iPSC-derived dopaminergic neurons from idiopathic PD patients.\",\n      \"method\": \"ChIP-seq/ChIP analysis of post-mortem brain; CRISPR/dCas9-SunTag-JARID1A system; qRT-PCR; Western blot; iPSC-derived dopaminergic neurons; NeuN-sorted neuronal nuclei\",\n      \"journal\": \"EMBO molecular medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — locus-specific histone modification editing with functional validation; patient post-mortem tissue plus iPSC model; multiple orthogonal methods; single lab\",\n      \"pmids\": [\"33428332\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"The H50Q SNCA mutation increases the rate of alpha-synuclein aggregation into amyloid fibrils in vitro, whereas the G51D mutation has the opposite effect (decreased aggregation rate), yet both mutant proteins can be seeded to form intracellular aggregates by exogenous amyloidogenic seeds and promote cellular toxicity under stress conditions.\",\n      \"method\": \"Recombinant protein aggregation assay (bis-styrylbenzene fluorometry), sedimentation analysis, electron microscopy, atomic force microscopy, cell-based aggregation seeding assay, cell viability assay\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with multiple biophysical methods plus cell-based validation; single lab\",\n      \"pmids\": [\"24984882\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Cryo-EM structures of alpha-synuclein filaments extracted from a case of juvenile-onset synucleinopathy (caused by a 21-nucleotide SNCA duplication) reveal a novel fold (residues 36–100 forming a compact core) that differs from Lewy body disease and MSA folds; the fold shares partial structural similarity with MSA protofilament substructures and contains a non-proteinaceous cofactor binding site; in vitro assembly of recombinant wild-type and insertion-mutant alpha-synuclein did not reproduce the JOS fold.\",\n      \"method\": \"Electron cryo-microscopy (cryo-EM) structure determination of patient-derived sarkosyl-insoluble filaments; in vitro assembly of recombinant proteins; mass spectrometry\",\n      \"journal\": \"Acta neuropathologica\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — atomic-resolution cryo-EM structure of patient-derived filaments with in vitro validation; single study but rigorous structural method\",\n      \"pmids\": [\"36847833\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Autophagy-lysosomal pathway (ALP) inhibition by bafilomycin A1 reduces intracellular SNCA aggregation but increases secretion of smaller oligomeric SNCA species predominantly via exosomes and RAB11A-associated pathways, whereas high-aggregated SNCA is secreted by membrane shedding; the secreted oligomers exacerbate microenvironmental toxicity.\",\n      \"method\": \"Cell culture model of SNCA aggregation; SNCA transgenic mice; pharmacological ALP inhibition (bafilomycin A1); immunoprecipitation; ELISA; live-cell imaging; exosome isolation; inflammation and cell-damage assays\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal approaches (cell model + mouse model + exosome fractionation + pathway inhibition); single lab\",\n      \"pmids\": [\"25484190\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Loss of GBA (glucocerebrosidase) function increases SNCA levels by inhibiting autophagy via PPP2A (protein phosphatase 2A) inactivation through Tyr307 phosphorylation; activation of PPP2A with C2-ceramide or rapamycin reverses GBA knockdown-induced SNCA accumulation.\",\n      \"method\": \"siRNA knockdown of GBA in SK-N-SH cells and primary rat cortical neurons; pharmacological inhibition; Western blot; immunohistochemistry; flow cytometry; rat striatum in vivo model\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockdown with pharmacological rescue in multiple cell types and in vivo; single lab, mechanistic pathway placement\",\n      \"pmids\": [\"26378614\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"BAG3 interacts with HSP70 and sequestosome 1 (SQSTM1/p62) and co-localizes with these proteins and LC3 puncta in TH-positive neurons; BAG3 overexpression enhances autophagic degradation of SNCA, and this effect is prevented by ATG5 knockdown, placing BAG3 upstream of macroautophagy in SNCA clearance.\",\n      \"method\": \"Immunoprecipitation; immunostaining; Western blot; BAG3 overexpression and knockdown in PC12 cells; SNCAA53T transgenic mice; ATG5 siRNA knockdown\",\n      \"journal\": \"Neurobiology of aging\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP plus epistasis (ATG5 KD rescue) in cell lines and transgenic mice; single lab\",\n      \"pmids\": [\"28941726\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ABL1 tyrosine kinase is activated by SNCA expression (via phosphorylation) and in turn increases SNCA levels; inhibition of ABL1 with Nilotinib facilitates autophagic clearance of SNCA, shifting SNCA from autophagic vacuoles to lysosomes in transgenic and lentiviral mouse models.\",\n      \"method\": \"Lentiviral SNCA expression in mouse substantia nigra; lentiviral Abl overexpression; Nilotinib pharmacological treatment; subcellular fractionation; Western blot; transgenic mouse model\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic and pharmacological manipulation with subcellular fractionation; multiple model systems; single lab\",\n      \"pmids\": [\"23787811\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CTSD (cathepsin D) is a lysosomal protease critical for SNCA degradation; recombinant human pro-CTSD (rHsCTSD) is endocytosed by neuronal cells, trafficked to lysosomes, and matured into an active enzyme that reduces insoluble SNCA in iPSC-derived dopaminergic neurons from PD patients with A53T SNCA mutation and in ctsd-deficient mouse brain.\",\n      \"method\": \"Recombinant protein treatment; immunofluorescence; Western blot; iPSC-derived dopaminergic neurons; ctsd-knockout mice; lysosomal activity assays; structured illumination microscopy\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — enzyme replacement approach with functional validation in patient-derived neurons and mouse model; single lab, multiple orthogonal readouts\",\n      \"pmids\": [\"35287553\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"In SNCA knock-in mice expressing aSyn-GFP under native regulatory elements, aSyn-GFP disperses from synaptic vesicles upon membrane depolarization, establishing that alpha-synuclein dynamically associates with synaptic vesicles and releases upon neuronal activity.\",\n      \"method\": \"Snca-GFP knock-in mouse; live imaging of synaptic terminals; membrane depolarization; confocal microscopy; intracerebral injection of preformed fibrils\",\n      \"journal\": \"eNeuro\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct live-imaging experiment in physiological knock-in model with functional stimulus; single lab\",\n      \"pmids\": [\"32788297\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"miR-30b directly binds to the 3'-UTR of SNCA mRNA and suppresses SNCA protein expression in SH-SY5Y cells, as demonstrated by luciferase reporter assay; miR-30b overexpression reduces SNCA protein levels and attenuates MPP+-induced apoptosis.\",\n      \"method\": \"Luciferase 3'-UTR reporter assay; miR-30b mimics/inhibitors transfection; Western blot; cell viability (CCK assay); apoptosis markers\",\n      \"journal\": \"Brain and behavior\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — direct 3'-UTR binding validated by luciferase assay with functional phenotypic rescue; single lab, single reporter method for binding\",\n      \"pmids\": [\"32154657\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"SNCA mRNA transcript levels are significantly reduced in neurons containing compact alpha-synuclein inclusions (but not in neurons with punctate or no alpha-synuclein staining) in the substantia nigra and amygdala of LBD patients, predominantly in the cytoplasmic compartment, suggesting progressive depletion of SNCA transcription or mRNA as inclusions form.\",\n      \"method\": \"RNAscope in situ hybridization combined with immunofluorescence for disease-associated alpha-synuclein in post-mortem LBD brain; single-nucleus RNA sequencing of non-diseased frontal cortex\",\n      \"journal\": \"Acta neuropathologica communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — quantitative in situ hybridization with immunofluorescence co-localization in patient tissue plus single-nucleus RNA-seq; single study\",\n      \"pmids\": [\"37996943\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"A novel SNCA A30G mutation causes a local perturbation of the intrinsically disordered structure of alpha-synuclein, slightly perturbs membrane binding, and promotes fibril formation in vitro.\",\n      \"method\": \"Biophysical characterization of recombinant A30G alpha-synuclein by NMR and other methods; fibril formation assay; whole exome sequencing and haplotype analysis\",\n      \"journal\": \"Movement disorders\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — biophysical characterization with fibril assay; single lab report of novel mutation\",\n      \"pmids\": [\"33617693\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"NACP (alpha-synuclein) is loosely associated with the plasma membrane, endomembrane system, and occasionally the membrane of secretory alpha-granules in platelets, as determined by immunogold electron microscopy.\",\n      \"method\": \"Immunogold electron microscopy of human platelets; immunoblotting; phorbol ester-induced megakaryocytic differentiation of K562 cells\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — direct subcellular localization by immunogold EM; single lab, single localization method\",\n      \"pmids\": [\"9299413\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"SNCA encodes alpha-synuclein, a natively unfolded presynaptic protein that dynamically associates with synaptic vesicles and disperses upon membrane depolarization; its expression is regulated at multiple levels including transcriptional modulation by the NACP-Rep1 microsatellite (via PARP-1 binding) and epigenetic control through DNA methylation at intron 1 and H3K4me3 at the promoter; alpha-synuclein binds amyloid-beta peptides via its NAC domain and promotes Aβ aggregation; pathogenic missense mutations (e.g., H50Q, G51D, A30G) divergently alter fibril formation kinetics; the protein is cleared primarily through the autophagy-lysosomal pathway involving CTSD, BAG3-HSP70-p62 complexes, and CMA (LAMP2A-dependent), with GBA deficiency impairing this clearance via PPP2A inactivation and ABL1 activation also impeding autophagic flux; excess or aggregated alpha-synuclein is secreted extracellularly via exosomes (RAB11A-associated) or membrane shedding, and cryo-EM has revealed that distinct disease-specific protein folds (differing between Lewy body disease, MSA, and juvenile-onset synucleinopathy) underlie the spectrum of synucleinopathies.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"SNCA encodes alpha-synuclein, a natively unfolded, intrinsically disordered presynaptic protein that exists in solution as a mixture of rapidly equilibrating extended conformers lacking stable secondary structure or a hydrophobic core [#0, #2]. In neurons it dynamically associates with synaptic vesicles and disperses upon membrane depolarization, linking its membrane interactions to neuronal activity [#14], and it is loosely associated with plasma and endomembranes [#18]. Through its central NAC domain alpha-synuclein binds amyloid-beta peptides and promotes their aggregation, and this same aggregation-prone region drives its own conversion into amyloid fibrils [#1]; pathogenic missense mutations divergently tune this process, with H50Q accelerating and G51D slowing fibril formation while A30G locally perturbs the disordered structure to promote fibrillization [#7, #17]. Cryo-EM of patient-derived filaments establishes that distinct disease-specific folds underlie the synucleinopathy spectrum, including a novel compact fold (residues 36–100) in juvenile-onset disease that cannot be reproduced by in vitro assembly of recombinant protein, implicating a non-proteinaceous cofactor [#8]. SNCA dosage is controlled at multiple regulatory layers: transcriptionally by the upstream NACP-Rep1 microsatellite, which recruits PARP-1 to repress transcription [#4]; epigenetically by DNA methylation at intron 1 and H3K4me3 at the promoter, both of which directly tune mRNA and protein levels [#5, #6]; and post-transcriptionally by miR-30b binding the 3'-UTR [#15]. Alpha-synuclein is cleared chiefly through the autophagy-lysosomal pathway, requiring lysosomal cathepsin D for degradation [#13] and a BAG3–HSP70–p62 complex that routes it into macroautophagy [#11]; this clearance is impaired by GBA loss acting through PPP2A inactivation [#10] and by ABL1 kinase activation [#12], while autophagy blockade redirects oligomeric species to exosomal secretion [#9].\",\n  \"teleology\": [\n    {\n      \"year\": 1995,\n      \"claim\": \"Established that alpha-synuclein physically engages amyloid-beta through its NAC domain and promotes Aβ aggregation, defining the aggregation-prone module central to its later disease biology.\",\n      \"evidence\": \"Filter-binding, deletion mutagenesis (NAC-deleted mutant), and aggregation assays with recombinant protein\",\n      \"pmids\": [\"7568089\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish whether NAC-mediated self-assembly occurs under physiological conditions\", \"No structural model of the bound complex\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Resolved the basic biophysical nature of the protein, showing it is natively unfolded rather than globular, which reframed how its function and aggregation must be understood.\",\n      \"evidence\": \"Analytical ultracentrifugation, CD, FTIR, UV on purified protein, confirmed by independent gel-filtration/proteolysis study (1997)\",\n      \"pmids\": [\"8901511\", \"9085269\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not address conformations adopted upon membrane or partner binding\", \"No in-cell conformational data\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Provided the first subcellular localization, placing the protein at plasma and endomembranes and secretory granule membranes.\",\n      \"evidence\": \"Immunogold electron microscopy of human platelets\",\n      \"pmids\": [\"9299413\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single localization method without neuronal context\", \"Did not define membrane-binding determinants\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Identified the upstream NACP-Rep1 microsatellite as a cis-regulatory modulator of SNCA transcription, providing a dosage-control mechanism relevant to expression-driven disease.\",\n      \"evidence\": \"Luciferase reporter assays with deletion and allele-specific constructs in neuroblastoma cells\",\n      \"pmids\": [\"11751692\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Did not identify the trans-acting factor\", \"Cell-culture reporter context only\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Named PARP-1 as the trans-acting factor binding NACP-Rep1 to repress SNCA, mechanistically completing the upstream regulatory model.\",\n      \"evidence\": \"Rep1 pulldown/MS, EMSA, ChIP, PARP-1 inhibition, and endogenous mRNA qRT-PCR in SH-SY5Y cells\",\n      \"pmids\": [\"15672325\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish in vivo relevance in brain\", \"Connection between PARP-1 enzymatic activity and repression incompletely defined\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Defined a feed-forward loop in which ABL1 kinase activation by alpha-synuclein impedes its own autophagic clearance, identifying a druggable node (Nilotinib).\",\n      \"evidence\": \"Lentiviral SNCA/Abl expression, Nilotinib treatment, subcellular fractionation in transgenic and lentiviral mouse models\",\n      \"pmids\": [\"23787811\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct phosphorylation substrate relationships not fully mapped\", \"Single lab\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Showed that pathogenic missense mutations divergently alter fibril formation kinetics, dissociating aggregation rate from cellular toxicity potential.\",\n      \"evidence\": \"Recombinant aggregation assays (fluorometry, EM, AFM) plus cell-based seeding and viability for H50Q and G51D\",\n      \"pmids\": [\"24984882\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve mutation-specific fibril architecture\", \"Stress-condition toxicity mechanism not defined\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Linked autophagy capacity to secretion route, demonstrating that ALP inhibition lowers intracellular aggregation but redirects oligomers to exosomal/RAB11A and shedding-based secretion that worsens microenvironmental toxicity.\",\n      \"evidence\": \"Cell and transgenic mouse models, bafilomycin A1, exosome fractionation, toxicity assays\",\n      \"pmids\": [\"25484190\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular machinery selecting exosome versus shedding routes not defined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Established intron 1 DNA methylation as a direct, editable lever on SNCA expression with phenotypic consequences in patient neurons.\",\n      \"evidence\": \"dCas9-DNMT3A targeted methylation in iPSC-derived dopaminergic neurons from an SNCA-triplication patient, with ROS and viability rescue\",\n      \"pmids\": [\"30266652\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous regulators establishing this methylation unknown\", \"Single patient line\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Placed GBA loss-of-function upstream of SNCA accumulation through a PPP2A-inactivation, autophagy-suppressing mechanism, mechanistically connecting a major genetic risk gene to clearance failure.\",\n      \"evidence\": \"GBA siRNA knockdown with PPP2A-activating rescue in cells, neurons, and rat striatum\",\n      \"pmids\": [\"26378614\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Precise step of autophagy regulated by PPP2A not pinpointed\", \"Single lab\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Defined a BAG3–HSP70–p62 chaperone module that channels alpha-synuclein into macroautophagy, identifying the adaptor machinery for its degradation.\",\n      \"evidence\": \"Co-IP, colocalization, BAG3 gain/loss with ATG5-knockdown epistasis in PC12 cells and A53T transgenic mice\",\n      \"pmids\": [\"28941726\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Reciprocal validation of each interaction limited\", \"Selectivity for alpha-synuclein over other substrates unclear\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Demonstrated activity-dependent synaptic vesicle association in a physiological knock-in model, grounding the protein's normal presynaptic role.\",\n      \"evidence\": \"Snca-GFP knock-in mouse with live terminal imaging during depolarization\",\n      \"pmids\": [\"32788297\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of dispersal for vesicle cycling not defined\", \"Did not identify vesicle-binding partners\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identified H3K4me3 enrichment at the SNCA promoter in PD substantia nigra and showed locus-specific demethylation lowers expression, adding a histone-mark regulatory layer.\",\n      \"evidence\": \"ChIP on post-mortem brain plus dCas9-SunTag-JARID1A editing in SH-SY5Y and iPSC-derived neurons\",\n      \"pmids\": [\"33428332\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Writers/erasers maintaining the mark endogenously not defined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Established miR-30b as a direct 3'-UTR-binding repressor of SNCA with protective phenotypic effects, adding post-transcriptional control.\",\n      \"evidence\": \"Luciferase 3'-UTR reporter, miR-30b mimics/inhibitors, viability and apoptosis assays in SH-SY5Y under MPP+\",\n      \"pmids\": [\"32154657\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single reporter method for binding without endogenous target validation\", \"In vivo relevance untested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Showed that SNCA mRNA is depleted specifically in neurons bearing compact inclusions, linking inclusion formation to transcript loss.\",\n      \"evidence\": \"RNAscope with immunofluorescence in post-mortem LBD brain plus single-nucleus RNA-seq\",\n      \"pmids\": [\"37996943\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Causal direction (depletion driving versus following inclusions) unresolved\", \"Correlative tissue analysis\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Characterized the A30G mutation as a local disorder perturbation that promotes fibrillization, expanding the genotype–aggregation map.\",\n      \"evidence\": \"NMR and biophysical characterization with fibril assay, plus exome/haplotype analysis of patient\",\n      \"pmids\": [\"33617693\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cellular toxicity not directly assessed\", \"Single-family report\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identified cathepsin D as the lysosomal protease executing SNCA degradation and showed enzyme delivery reduces insoluble protein, defining a terminal clearance step.\",\n      \"evidence\": \"Recombinant pro-CTSD uptake/maturation in iPSC-derived A53T neurons and ctsd-knockout mouse brain\",\n      \"pmids\": [\"35287553\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cleavage sites and fragment fate not mapped\", \"Single lab\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Resolved disease-specific atomic folds of patient-derived filaments, including a novel juvenile-onset fold not reproducible in vitro, establishing structural strain diversity and a cofactor requirement.\",\n      \"evidence\": \"Cryo-EM of sarkosyl-insoluble filaments from JOS, with recombinant in vitro assembly and mass spectrometry\",\n      \"pmids\": [\"36847833\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the non-proteinaceous cofactor unknown\", \"Mechanism generating strain-specific folds in vivo undefined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How activity-dependent synaptic function, multilayered dosage control, and clearance failure converge to nucleate the distinct cofactor-dependent fibril strains that define each synucleinopathy remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No mechanism linking native synaptic-vesicle biology to strain-specific aggregation\", \"Identity of cofactors templating disease-specific folds unknown\", \"How clearance impairment selects secretion/spreading routes in vivo undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [14, 18]},\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [7, 8]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [18]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [14, 9]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [9, 10, 11, 12, 13]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [7, 8, 17]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [4, 5, 6]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"PARP1\", \"BAG3\", \"HSPA8\", \"SQSTM1\", \"ABL1\", \"CTSD\", \"APP\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"tie","faith_supported":5,"faith_total":6,"faith_pct":83.33333333333333}}